Physician profile
Corey E Goldsmith
NPI 1780877472
$1,506.43
in general payments reported to CMS, 2019-2025
11 companies · $19.25 in 2025
The $19.25 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $296 · 2021: $20.23 · 2022: $45.54 · 2024: $18.13 · 2025: $19.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $497.69 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $414.96 | 2019-2022 | |
| Biogen, INC. | $370.66 | 2019-2024 | Vumerity, Tysabri |
| Genentech USA, INC. | $55.04 | 2019 | |
| Merz North America, INC. | $40.45 | 2019 | |
| Allergan, INC. | $22.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.67 | 2022 | |
| Eisai INC. | $22.26 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.74 | 2019 | |
| Abbvie INC. | $19.25 | 2025 | |
| Ucb, INC. | $18.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.